Sanofi, the biopharmaceutical company, has witnessed a rollercoaster of events recently. The company experienced a setback when their oral TNF inhibitor failed to meet expectations in a phase 2 psoriasis trial. However, Sanofi's Altuviiio is nearing blockbuster status, thanks to surging Dupixent sales. Dupixent, the company's patented drug, continues to drive profitability and growth. The CEOs of Sanofi and Novartis have criticized EU price control as US contemplates drug price parity with other nations. The tech arm of the company has indicated that remote work hampers innovative discussions. While, regulatory bodies have approved Sanofi's bleeding disorder therapy, it had to return cancer NK cell engager to Innate due to an autoimmune pivot. As part of their strategic growth, Sanofi has committed significant investment into various healthcare researches and collaborations. The Q1 2025 Earnings Top Estimates further indicating Dupixent's leading contribution to sales. The French drugmaker reported a 20% growth in Q1 profits and projected strong rebounds in its annual profit.
Sanofi News Analytics from Mon, 23 Sep 2024 12:06:18 GMT to Sat, 26 Apr 2025 12:19:43 GMT -
Rating 5
- Innovation 3
- Information 6
- Rumor -3
